A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Study Overview
=================
Brief Summary
-----------------
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.

Detailed Description
-----------------
The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.

Official Title
-----------------
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin

Conditions
-----------------
Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection, Cytomegalovirus Infections

Intervention / Treatment
-----------------
* Dietary Supplement: Gene-Eden-VIR/Novirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Latent viral infection with either HSV, HPV, VZV, EBV, or CMV Taking Gene-Eden-VIR/Novirin Exclusion Criteria: Use of other antiviral treatments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Herpes Simplex Virus Infection<br>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months | Dietary Supplement: Gene-Eden-VIR/Novirin<br> <br> |
| Human Papillomavirus Infection<br>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months | Dietary Supplement: Gene-Eden-VIR/Novirin<br> <br> |
| Epstein-Barr Virus Infection<br>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months | Dietary Supplement: Gene-Eden-VIR/Novirin<br> <br> |
| Cytomegalovirus Infection<br>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months | Dietary Supplement: Gene-Eden-VIR/Novirin<br> <br> |
| Varicella Zoster Virus Infection<br>Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months | Dietary Supplement: Gene-Eden-VIR/Novirin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of symptoms |  | one year | 
| duration of symptoms |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to first recurrence |  | one year |